Core Insights - Allergan Aesthetics has launched a new referral program called "Refer a Friend" within its Allē Loyalty Rewards Program, allowing members to earn rewards for referring new users [1][2][3] - The program incentivizes both the referrer and the new user, with new users receiving up to $50 off their first purchase and referrers earning $10 for each successful referral [3][4] - The Allē program currently serves over seven million members across 27,000 practices, making it a significant player in the aesthetics market [4] Company Overview - Allergan Aesthetics is a subsidiary of AbbVie, focusing on developing, manufacturing, and marketing a range of aesthetic products, including injectables and skin care [6][7] - The company aims to provide innovation, education, and exceptional service to its customers, emphasizing a personal touch in its offerings [6] Market Insights - The referral program is based on market research indicating that 92% of consumers trust referrals from friends and family more than other advertising forms, highlighting the importance of word-of-mouth in the aesthetics industry [2] - The Allē program is unique in the aesthetics market as it allows members to earn points on over 50 non-Allergan Aesthetics treatments and brands, enhancing its appeal to consumers [4]

AbbVie (ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Skyrizi (risankizumab) in the EU to treat adults with moderately to severely active ulcerative colitis (UC).The eligible patient population includes UC patients who have had an inadequate response, lost response, or were intolerant to either conventional or biologic therapy. The recommended treatment regime with AbbVie’s Skyriz ...

NORTH CHICAGO, Ill., June 3, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 9:00 a.m. Central time.A liv ...

The financial media does its best to keep you informed about what’s happening in the market. However, this has the effect of giving significant attention to a handful of leaders or laggards. That creates an opportunity for investors who have the patience to look for must-own overlooked stocks.  Overlooked stocks are not necessarily underperforming the market. In some cases, these stocks simply are slow and steady at a time when investors want to find the newest and brightest shiny object.  However, not ever ...

AbbVie (ABBV) shares rallied 3.2% in the last trading session to close at $161.24. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.8% loss over the past four weeks.The rise in share price came after management announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on its regulatory filing seeking label expansion for blockbuster immunology drug Skyrizi in ulc ...

The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ulcerative colitis (UC)1,2In both trials, the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including endoscopic improvement** and histologic-endoscopic mucosal improvement,† were met1,2UC is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affec ...

AltaybIntroduction I just read an interesting Wall Street Journal article that discussed the accelerating trend of shoppers buying store brands to deal with rising inflation. As we can see below, demand for store brands has exploded, including products in categories where companies tend to have low customer loyalty, like dish care, air fresheners, pasta, candy, and others. The Wall Street JournalLooking at the chart below, we see that roughly $0.20 of every dollar spent in grocery stores goes towards pr ...

New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC. Data from a first-in-human study of ABBV-706, a potential best-in-class SEZ6 directed ADC, in small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine neoplasms (NENs). Data from the primary analysis of the Phase 2 LUMINOSITY trial evaluating Telisotuzumab ved ...

For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower.Let’s get some of the bad stuff out of the way first. Biotech stocks – even the established players – can be volatile. A miss in the clinical process to commercialize a therapeutic could lead to significant losses. And there’s really no way of reliably forecasting such outcomes. Plus, the sector isn’t always known for delivering predictable financial performanc ...

AbbVie's returns haven't been great this year, but investors shouldn't overlook this promising growth stock.Nvidia (NVDA 2.57%) has been a great stock to own, and it could remain that way for long-term investors. However, the problem is that it's trading at nearly 40 times its future profits. At such a high valuation, it sets a high bar for the business and effectively prices in a lot of future growth already. It could make it difficult for the stock to continue to generate high returns. Even if it does, at ...